CASPASE 9 GENE EXPRESSION AND CASPASE 9 PROTEIN IN CHRONIC MYELOID LEUKEMIA IN IRAQ

Abdullah W. K. Maha F. A.
Researcher Assit. Prof.
Dept. Of Biotechnology, Coll. Of Sci. University of Baghdad, Iraq.
e.mail: maha. fakhry@sc.uobaghdad.edu.iq

ABSTRACT
The following study was carried out to investigate gene expressions of the CASPASE 9 gene and CASPASE 9 protein with the development of chronic myeloid leukemia (CML) in Iraq. The differences in the expression of this gene between patients and healthy controls were included. The correlation of age and gender with CML occurrence comparing with controls was studied. Results showed significant increases in the mean of gene expression level (ΔCt) of patient groups compared to the corresponding ΔCt means in control group, also the gene expression folding (2^-ΔΔCt) of CASPASE 9 gene reflect significant differences in the expression showed the highest level in CML patients which reached to (16.19), the level of CASPASE 9 protein was (1.025 ng/ml) in patients with CML compared to control groups with significant differences. On the other hand no significant differences were exhibited according to age and gender between CML patients and control, this result suggest that CML can affect all ages and occur in both male and females.

Key words: patients, age, gender, healthy, chronic myeloid
INTRODUCTION
CML is a chronic myeloproliferative disorder with an initially chronic course lasting for 3–5 years, this proliferation of mutant stem cell will generate some differentiated cells leading to an expending in the total myeloid mass (5). The causes of CML are essentially unknown and the risk factor is exposure to ionizing radiation, chemicals such as benzene (25,26). An increased prevalence of other malignancies and autoimmune diseases were found prior to CML diagnosis, indicating a genetics or acquired increased predisposition to cancer and autoimmunity in CML patients(9) CML is one of the chronic myeloproliferative disorders, resulting from a characteristic Philadelphia chromosomal abnormality, t (9; 22) (q34q11). The molecular consequence of this chromosomal translocation is production of a hybrid BCR-ABL. A genetic change takes place in an immature myeloid cell, which make red blood cells, platelets, and most types of white blood cells except lymphocytes (22). CML frequently affects adults but very rarely in children (7). Apoptosis is a natural cell death mechanism. It plays a crucial role in development and homeostasis in long-lived mammals. It is the process of programmed cell death that occurs in response to environmental stimuli. Regulation of apoptosis is important for normal growth and homeostasis, during development, embryogenesis, and modification of normal tissues, also cancer treatment. Disorders of abnormal induction of apoptosis can cause severe outcomes. Impaired regulation of apoptotic mechanisms provides an opportunity to growth cancerous cells and chemo-resistance (14). A wide range of circumstances, including DNA damage, can activate the apoptotic pathway or uncontrolled proliferation (4). Cancer cells can avoid apoptosis in a variety of ways, including inhibiting caspase activity. Caspases may also exert non-apoptotic functions, such as influencing cell proliferation, migration and the immune response. They are involved in the differentiation of several cell types, including macrophages, and may have a role in the secretion of cytokines and growth factors (28). Caspases are cysteine-dependent aspartate-specific proteases has ability to cleaving protein, the active site to cleave aspartic acid peptide bonds within proteins, after aspartic acid residues including cell death, Inflammation, Caspases are synthesized as inactive precursors termed pro-caspases, Caspases are present in the cytoplasm as inactive pro-caspases. Caspase can be classified to differentiate between initiator caspases, triggered by death receptor clustering, and caspase effector. Initiator caspases represented by caspases 2, 8, 9, and 10 while effector caspases are represented by caspases 3, 6, and 7 (21). Initiator caspases activate effector caspases in response to specific cell death signals, and effector caspases cleave various cellular proteins to trigger apoptosis (6). Caspase 9 has a vital role in intrinsic pathway. It is initiated by release of cytochrome c from mitochondria in response to many cytotoxic signals such as DNA damage, cytotoxic drugs and growth factor withdrawal. Cytochrome c is a peripheral protein of the mitochondrial inner membrane interacts with Apaf-1, proCASP-9 and dATP results in formation of multiprotein complex apoptozome. apoptosome serves as a recruitment platform that promotes procaspase-9 activation (29). Once a bond to apoptozome is formed, caspase-9 is activated, which triggers other effectors such as caspases 3 and 7 (27). Caspase 9 is mapped on chromosome 1p36.21 which is important in the mitochondrial pathway due to many factors, such as chemotherapy and radiation. Caspase 9 is activated on the apoptosis complex to preserve catalytic status and is thought of including homo-dimerization monomeric zymogens. Miscarriage to activate caspase 9 has intensive pathophysiological implications, contributing to cancer as well as degenerative and developmental disorders. Other proteins and small molecules included in the regulation of caspase 9 to attained regulation of the apoptotic cycle (18, 20).

MATERIALS AND METHODS
Patients and control
Fifty patients with CML were included in this study with an age ranging between (4-75) years old divided according to gender into (19) male and (31) female, were obtained from Mosul city (Iben Sina Hospital) and Erbil city (Nanakaly Hospital), corresponding to fifty
controls with an age ranging between (20-65) years old included (27) male and (23) female and were diagnosed with CML on the basis of complete blood picture (CBC) along with bone marrow examination, and test of \textit{BCR-ABL} gene to diagnose CML patients.

**Blood collection**
Samples were taken from each patients and control and the collected blood put in TRI zol TM Reagent containing tube for RT-qPCR analysis.

**Total RNA Extraction with TRIzol**
RNA was isolated from sample according to the protocol of TRIzolTM Reagent as the following:

**Sample lysis**
For each tube, 0.5 mL of blood was added to 0.5 mL of TRIzol TM Reagent, the lysate was homogenized by pipetting up and down several times.

**Three phase's separation**
Each tube’s lysate was treated with 0.2 mL chloroform before the tube cap was secured. To separate the lower organic phase, interphase, and colorless centrifuged for 10 minutes at 12,000 rpm. A new tube was filled with the aqueous phase containing the RNA.

**RNA precipitation**
In the aqueous phase, 500µl of isopropanol was added and left for 10 minutes before centrifuging at 12,000 for 10 minutes rpm. Total RNA precipitated into a white gel-like pellet at the bottom of the tube. After that, the supernatant is discarded.

**RNA washing**:
For each tube, 0.5mL of 70% ethanol was added and vortex briefly then centrifuge for 5 minutes at 10000 rpm. Ethanol then aspirated and air-dried the pellet.

**RNA solubility**
Pellets were incubated in a water bath or heat block set at 55–60°C for 10–15 minutes after rehydration in 100µl of Nuclease Free Water.

**RNA purity and concentration measurements**
The purity and concentration of the extracted lysates is measured using a spectrophotometer Nano drop (Q5000 (UV-VIS)). The purity is calculated by calculating the optical density (OD) ratio at 260/280nm. while the concentration is measured in ng/l (absorption wavelength of protein and DNA). The purity of RNA that is accepted is between 1.7 and 2. By using the equation

\[ V_n = C_0 \times V_o / C_n \]

The concentration of RNA samples is normalized to the lowest concentration of sample. Where, \( V_n \) is the volume of current sample that will be diluted by TDW to generate totally 100 µL, \( V_o \) is the normalized volume (equal to 100µL and \( C_0 \) is the lowest concentration.

**Primer design**
The NCBI Gen Bank database was used to obtain the cDNA sequences of the \textit{CASPASE 9} genes, as well as \textit{TEGT} as a housekeeping gene. Premier 3 software was used to design RT-qPCR primers with a melting temperature of 60 to 65 degrees Celsius, primer lengths of 18 to 23 nucleotides, and PCR amplicon lengths of 75 to 150 base pair as shown in Table 1.

**Gene Expression**

**cDNA synthesis from Mrna**
The GoTaq®1-Step RT-qPCR System kit (Promega, USA) was used to assess the expression of \textit{CASPASE 9} genes. It's a one-step RT-qPCR reagent method for quantitative RNA analysis. For effective, sensitive service, and one-step linear RT-qPCR quantification across a broad range of RNA template inputs, GoScriptTM Reverse Transcriptase and GoTaq®qPCR Master Mix are combined in the GoTaq®1-Step RT-qPCR S stem. According to the instructions of the manufacturerd company, In a reaction volume of 20 µl, the procedure was carried out. The total amount of RNA that needed to be reversed transcribed was 4 µl liters.

**Protocol**
Reverse transcription reactions should be assembled in RNase-free environment. The RNA templates and all reagents were thawed, and each solution was mixed gently. The RT FDmix tubes were placed on PCR tube rack. The reaction component was added to the RT FDmix tube as in Table 2.
Table 1. Primers sequences

| Primers   | Sequences                   | Annealing Temp (C) |
|-----------|-----------------------------|--------------------|
| CASPASE9 F | 5'-ACAGGGTCTGCTTTTCT-3'     |                    |
| CASPASE9 R | 5'-GCATTCACTCTGATCTTTCT-3'  | 60                 |
| TEGT F    | 5'TGCTGGATTTTGCATTCCTTACA-3' |                    |
| TEGT R    | 5'-ACGGCGCTGGCATAGA-3'      | 65                 |

Tubes were placed in a thermal cycler program as in Table 3

Table 2. Reaction volume and components of reverse transcription reaction used to prepare cDNA from total RNA

| Component         | Volume   |
|-------------------|----------|
| RT FDmix          | 1 tube   |
| Total RNA         | 4μl      |
| Nuclease-free H20 | up to 20μl|

Synthesized cDNA was immediately used as template for PCR or for long-term storage at -20°C.

Quantitative real time PCR (qRT–PCR):
The expression levels of CASPASE 9 gene was estimated by the reverse transcription-quantitative polymerase chain reaction (qRT-PCR) method, which is a sensitive technique for the quantification of steady-state mRNA levels. To confirm the expression of target gene, quantitative real time qRT-PCR SYBR Green assay was used.

Primer preparation
A primer for CASPASE 9 and TEGT working solution were prepared from the lyophilized primers after dissolving in nuclease free water according to the manufacture, to make a stock solution with a concentration of 100 μM for each primers and stored at -23°C. A working solution with a concentration of 10 μM was prepared by diluting 10μL of primers stock solution in 90 μL of nuclease free water and stored at( -23°C) until use. Primers sequences for CASPASE 9 gene was designed in the current study and synthesized by Alpha DNA Ltd (Canada) and stored lyophilized at -23°C. Primers sequences are shown in Table (1).The mRNA levels of endogenous control gene TEGT were amplified and used to normalize the mRNA levels of the tested genes. TEGT primers sequences are also show in Table 1. Quantitative real time PCR (qRT–PCR) was performed using the MIC-4 Real-time PCR System (AUSTRALIA).The gene expression levels and fold change were quantified by measuring the threshold cycle (Ct) employing the 2xqPCR Master Mix Kits components.Every reaction was done in a duplicate. The required volume of each Component was calculated according to the Table 4.

Table 3. Thermal cycler steps of conditions cDNA Reverse Transcription

| Step  | Step1 | Step2 | Step3 | Step4 |
|-------|-------|-------|-------|-------|
| Temperature | 25 ºC | 42 ºC | 85 ºC | 4 ºC |
| Time   | 10 min | 30 min | 10 min | ∞   |

Synthesized cDNA was immediately used as template for PCR or for long-term storage at -20°C.

Table 4. Components of quantitative real-time PCR used in gene expression experiment

| Components            | 1μL rxn |
|-----------------------|---------|
| qPCR master mix       | 5       |
| Nuclease free water   | 2       |
| Forward Primer (10μM) | 0.5     |
| Reverse Primer (10μM) | 0.5     |
| cDNA                  | 2       |

The cycling protocol was programed for the following optimized cycles and according to the thermal profile as shown in Table5
Table 5. Thermal profile of genes expression

| Step         | Temperature | Duration | Cycle |
|--------------|-------------|----------|-------|
| Enzyme activation | 95°C        | 5 min    | 1     |
| Denature     | 95°C        | 20 sec   |       |
| Annealing    | 60°C        | 20 sec   | 40    |
| Extension    | 72°C        | 20 sec   |       |

Using the real-time cycler software, the threshold cycle (CT) was calculated for each sample. All samples were run in duplicate and mean values were calculated. Expression data of selected genes were normalized against housekeeping. The ΔΔCt method by (19) was used as was recommended for data analysis and results were expressed as folding change in gene expression as follow: For each sample, the difference between the CT values (ΔCt) for each gene of target and the housekeeping gene was calculated as:

\[ \Delta C_t(\text{control}) = C_T(\text{gene}) - C_T(\text{HKG}) \]
\[ \Delta C_t(\text{patient}) = C_T(\text{gene}) - C_T(\text{HKG}) \]

The fold-change in gene expression was calculated as follow: 

\[ \text{Fold change} = 2^{-\Delta \Delta C_t} \]

Caspase 9 protein

A quantitative detection of caspase 9 in serum of patients with CML and healthy controls were detected according to the Elisa kit based on sandwich enzyme-linked immune-sorbet assay supplied from cell biolabs, Inc.USA.

Statistical analysis

Data were statistically analyzed by utilizing Sigma plot for Windows, version 12.5 Data were appeared as mean ± standard deviation (11).

RESULTS AND DISCUSSION

Quantitative Expression of CASPASE 9

Total RNA was extracted from all samples. The concentration of total RNA ranged from 69 to 190 ng/μl in patients with CML While it range from 80 to 191 ng/μl in healthy group. The purity of total RNA samples ranged from 1.80 to 1.92 while with control group it recorded form 1.81 to 1.94.

CDNA reverse transcription

On the second day of RNA extraction complementary DNA reverse transcription was conducted. A common primer reaction was applied since it was needed to have cDNA for caspase 9 gene and housekeeping x gene. The efficiency of cDNA concentration was determined through the efficiency of qPCR conducted later on. All steps were associated with perfect yield reflecting efficient reverse transcription. According to the Tm of each primer supplied in the manufactures instructions the Optimal primers annealing temperature was calculated depending on the following equation:

Meltiing Temperature (Tm) = 2 \times (A+T) + 4 \times (G+C).

The temperatures of melting for the reverse and forward primer were also calculated according to the above equation. The lowest temperature (°C) was chosen by comparing the annealing temperature for forward and reverse primers (24).

Quantitative expression of caspase 9 gene and housekeeping gene TEGT were assessed by Real Time Polymerase Chain Reaction, in which the relative quantitation method was used. The gene expression level was normalized to the level of a housekeeping gene and quantified by the ΔCt value and folding \(2^{-\Delta \Delta C_t}\) method as shown in Figures (1, 2) respectively.
Figure 1. Amplification plots of CASPASE 9 gene by RT-qPCR

Figure 2. Amplification plots of TEGT gene by RT-qPCR.

Figure 3. Melt curve of CASPASE 9 gene amplicons after RT-qPCR analysis showing single peaks. Threshold 0.014 starting at 80.86°C
A representative melt curve caspase 9 gene for samples analyzed by RT-PCR is shown Figure 3, in which, a single peak was observed for the amplicons. Such findings are explained that the melt curve represented a pure, single amplicon for each sample, and the specificity of amplification was considered to be great with intercalating dye assay.

**Expression level of CASPASE 9 gene in the studied groups**

The ΔCt mean of caspase 9 gene in blood samples of CML patients was (11.31) There was a significant increases \( p<0.001 \) in ΔCt mean of patient groups compared to the ΔCt means in control group as show in Table 6. Reveals significant differences in the expression caspase 9 mRNA and the level in CML patients reached 16.19 as shown Table 7.

| Gene expression Level ΔCt | Control (n=50) | Patient (n=50) | \( p \) |
|---------------------------|----------------|----------------|------|
| Caspase 9                 | 5.65 ± 1.22    | 11.31 ± 0.89   | 0.001|

*Table 6. Expression level (ΔCT) of Caspase 9 in CML patients and control groups*

| Genes                  | Gene expression \( (2^{ΔΔCt}) \) (mean± SD) | \( p \) |
|------------------------|-----------------------------------------------|------|
| Caspase 9              | 16.19 ± 5.52                                 | 0.001|

*Table 7. Mean of gene expression \( (2^{ΔΔCt}) \) of CASPAS 9 mRNA in patients group*

Caspase 9 proteins have been evaluated using the enzyme-linked immunosorbent assay. Mean of Caspase 9 protein levels in CML patients showed 1.025 ± 0.212 ng/ml compared with 6.974 ± 3.545 ng/ml in control groups as shown in table 8. The results statistically revealed a significant differences \( p>0.05 \) between the level of Caspase 9 protein between patients and healthy control group. These results were agreed with (15) who found CASP9 serum levels were significantly lower in the patient group with non-small cell lung cancer than in the control group. a significant correlation of serum caspase 9 levels were observed with severity of clinical state of amyotrophic lateral sclerosis and duration of the disease \( (p < 0.05) \) showing that caspase 9 is an important target in pathophysiology of amyotrophic lateral sclerosis (2,12). Also the inactive caspase 9 level was lower in the depigmented epidermis patient with vitiligo compared with the normally pigmented epidermis (16). Gene expression level of caspase 9 was higher in cases of CML patient when compared with healthy group, which reflect a vital role of Caspase 9 in confirming a diagnosis of CML and may explain to some extent the pathogenesis of disease (2, 8). The activity of caspase 9 is stimulated by dimerization, which leads to rapid autocatalytic cleavage, producing caspase 9. Caspase 9 initiated apoptosis is believed to reflect the susceptibility of cancer cells to chemotherapy drugs. Deregulated apoptosis system may lead to cancer development .similar results were also obtained by (10) .The current study focus on the importance of the Caspase 9 in the development of chronic myeloid leukemia and indicate the included of Caspase 9 in the CML phases. The probable explanation for the elevated Caspase 9 gene expression level in present study is that it may have a vital role in the pathophysiologic process in this disease. In summary Caspase 9 mRNA expression were significantly unregulated in CML patients compared to controls. The data suggest the role of Caspase 9 as valuable tools for the efficiency of target treatment of chronic myeloid leukemia in Iraq.

**Correlation of gender and age with CML and control groups**

The results show in table 9 and 10 related with gender and age of CML patients compared with control revealed no significant differences \( p>0.001 \) for both gender and age of CML patients and controls. Results are in agreement with (13). The percentage of patient male was 19% while control male 27%. Moreover, patient's female exhibit 31% while control female showed 23% as shown in table 9. Also the mean of patient’s age was 40.88 while the mean of controls age was 38.82 as shown in table 10. Our result was closer to the median age in Bangladesh was 40 years old.
while a median age in Europe 55 years old (14). Genetic factors might impact the age distribution of CML patients and the high cost of medication and monitoring was another challenge for patients in low-income countries (3, 23). These results reflect that CML disease could affect both male and female at any age.

Table 9. Frequencies of control and CML patients groups depending on gender

| Groups (n=50) | Gender | Proportion | P   |
|--------------|--------|------------|-----|
| Patient      | Male   | 19%        |     |
| Control      | Male   | 27%        | 0.11|
| Patient      | Female | 31%        |     |
| Control      | Female | 23%        |     |

Table 10. Means of age parameter in CML patients and control groups

| Parameter | Control (n=50) (mean± SD) | Patients (n=50) (mean± SD) | P  |
|-----------|---------------------------|----------------------------|----|
| Age (years) | 38.82 ± 9.54            | 40.88 ± 15.03             | 0.415|

REFERENCE

1. Abdulhasan, G. A. 2021. Lemon grass essential oil shows an antiproliferative effect on lung cancer cells and its role in expression of p53 gene. Iraqi Journal of Agriculture Sciences. 52 (2):359-366
2. Albano, F., A. Zagaria, L. Anelli, N. Coccaro, L. Impera, C. Minervini, A. Minervini, AR. Rossi, G. Tota, P. Casieri and G. Specchia, 2013. Gene expression profiling of chronic myeloid leukemia with variant t (9; 22) reveals a different signature from cases with classic translocation.” Molecular Cancer; 4 May, 12 - 36
3. Altaee, M. F., R. W. Younis and Z. K. Kamona 2020. Activity of Annona squamosa peels extract against two pathogenic bacteria and two blood cancer cell lines. Iraqi Journal of Agriculture Sciences .51 (6): 1496-1503
4. Arbise, J. L., M.Y. Bonner and L.C. Gilbert 2017. Targeting the duality of cancer. NPJ Precision Oncology, 1(1), 1-7
5. Buchdunger, E., A. Matter and B.J. Druker 2001. Ber-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta. ; 1551(1):11-8
6. Chang, H.Y. and X. Yang 2000. Proteases for cell suicide: functions and regulation of caspases, Microbiol. Mol. Biol. Rev. 64 (4):821–846
7. Duaa, A. S. 2020. Genetic Polymorphisms of Caspase 8 and 9 Genes in Myeloid Leukemia of Iraqi Patients, M.Sc. thesis. University of Baghdad. College of Science.64-65
8. Elsahookie, M.M., S. H. Cheyed and A. A. Dawood 2021. An overview on mechanism of gene expression regulation. Iraqi Journal of Agriculture Sciences. 52(2):454–460.
9. Erkan, S., S. Arinc, S. yilmaz, C. Altunok, F. Yaman and T. Isbir 2019. Investigation of caspase 9 gene polymorphism in patients with non-small cell lung cancer. Anticancer Research; 39 (5) 2437-2441
10. Extermann, E., and U. Wedding 2012. Comorbidity and geriatric assessment for older patients with hematological malignancies. A Review of the Evidence. J Ger Oncol; 3, 49-57
11. Forthofer, R. N., and E.S. Lee 2014. Introduction to biostatistics: a guide to design, analysis, and discovery. Elsevier.pp 323-331
12. Gunnarsson, N., M. Hoglund, L. Stenke, S. Wällberg-Jonsson, F. Sandin, M. Björkholm, A. Dreimane, M. Lambe, B. Markevîrn, U. Olsson-Strömberg, H. Wadenvik, J. Richter, and A. Själander 2016. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia; 30(7):1562-7
13. Hofny, E.R.M., H.I. Hasan, N.A. Mohamed, M.S. Bamatraf and A.M.M. Mahran 2017. Bcl-2, active caspase-9 and inactive caspase-9 levels as markers of apoptosis in the serum and tissue of vitiligo patients. Al-Azhar Assiut Medical Journal. 15 (2): 85-91
14. Hossain, M. S., M. S. Iqbal, M. A. Khan, M.G. Rabbani, H. Khatoon, S. Munira, MM. Miah, AL. Kabir, N. Islam, TF. Dipta, F. Rahman, A. Mottalib, S. Afrose, T. Ara, AR. Biswas, M. Rahman, AM. Abedin, M. Rahman, AB. Yunus, LW. Niessen and TA. Sultana 2014. Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer; 14; 14:438
15. Ilżecka. J. 2012. Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis. Neurol Sci.; 33(4): 825–829
16. Ibireal, JM., EA. Azab, S. Alzahani and M. Elsharaf 2019. Haematological and cytogenetic changes in CML patients treated with imatinib mesylate in Western
Libya. Hematology and Transfusion International Journal 7(3): 50–57
17. Johnstone, RW, AA. Rueflı and SW. Lowe 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell; 108(2):153–64.
18. Kalkavan, H., and D.R. Green 2018. MOMP, cell suicide as a BCL-2 family business. Cell Death and Differentiation, 25(1), 46–55
19. Kenneth, J. and M. Thomas 2001. Analysis of Relative Gene Expression Data Using RealTime Quantitative PCR and the 2-DDCT Method. Methods; 25: 402–408
20. Kim, B., Sanjay, KS, and K. Sung-Hoon 2014. Caspase-9 as a therapeutic target for treating cancer. Expert Opinion on Therapeutic Targets; 19(1): 113-127
21. Koenig, A., Russell, J.Q., Rodgers, W. A., and R.C. Budd 2008. Spatial differences in active caspase-8 defines its role in T-cell activation versus cell death. Cell Death and Differentiation, 15(11), 1701–1711
22. Melo, JV, Hughes, TP., and JF. Apperley 2003. Chronic Myeloid Leukemia. ASH Education Program Book; (1):132–152
23. Pasquini, MC. 2012. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology; 17(Suppl 1):S79-82
24. Patel, N. and N. Prakash 2013. Principle and Tools for Primer Design. Atmiya. Spandan. 1: 79 -95
25. Qin, A., J. Zhu, X. Liu, D. Zeng, M. Gu and C. Lv 2017. MicroRNA-1271 inhibits cellular proliferation of hepatocellular carcinoma. Oncol Lett; 14(6): 6783–6788
26. Reis, C., H. Reis, C. Araujo, C. Russell, S. Welsh, A. Sharip and P. Kim 2017. Inhalational chemical exposure resulting in myelogenous leukemia. International Journal of Biomedical Research; 8 (02): 108-110
27. Shaw, J., and LA. Kirshenbaum 2006. HAX-1 represses post-mitochondrial caspase-9 activation and cell death during hypoxia-reoxygenation.Circ Res.99:336–338
28. Sordet, O., C. Rébé, S. Plenchette, Y. Zermati, O. Hermine, W. Vainchenker, C. Garrido, E. Solary and L. Dubrez-Daloz 2002. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood; 100: 4446–4453
29. Wurstle, M.L, M.A. Laussmann and M. Rehm 2012. The central role of initiator caspase-9 inapoptosis signal transduction and theregulation of its activation and activity on the apoptosome. Exp Cell Res; 318(11):1213-208.